Ying, M. (2018). Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. American Society of Hematology (ASH).
Chicago Style (17th ed.) CitationYing, M. Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2. American Society of Hematology (ASH), 2018.
MLA (9th ed.) CitationYing, M. Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2. American Society of Hematology (ASH), 2018.
Warning: These citations may not always be 100% accurate.